Clinical Deal Signal

{
  "acquisition_targets": [
    {
      "asset": "Mazdutide (IBI362)",
      "clinical_data": "Phase 3 China data strong — 14.5% body weight reduction at 52 weeks",
      "company": "Innovent Biologics (China)",
      "deal_comp": "Structure Day1 Biosciences (Pfizer) $1.25B + milestones — Phase 2 obesity asset. Mazdutide later-stage = premium.",
      "deal_rationale": "Ex-China rights available. Differentiated vs. semaglutide on muscle preservation. Lilly or Roche most likely acquirers.",
      "estimated_deal_value_usd_m": "800-2000",
      "mechanism": "GLP-1/glucagon dual agonist",
      "probability": "High",
      "risks": [
        "China geopolitical risk for IP transfer",
        "Phase 3 US/EU data needed before deal close"
      ],
      "stage": "PHASE3"
    }
  ],
  "deal_timing_signals": "Obesity M&A is peak hot. Big pharma BD teams are actively searching — any Phase 2 readout with >10% weight loss and clean safety profile will attract inbound interest within 3-6 months of data release.",
  "licensing_opportunities": [
    {
      "asset": "CT-388 (dual GLP-1/GIP)",
      "company": "Carmot Therapeutics (acq. Roche)",
      "estimated_license_value_usd_m": "300-800",
      "notes": "Roche may sublicense ex-US rights to regional partners in Asia/LatAm"
    }
  ],
  "market_context": {
    "approved_leaders": [
      "Semaglutide (Novo Nordisk — Wegovy)",
      "Tirzepatide (Lilly — Zepbound)"
    ],
    "big_pharma_strategic_need": "Roche, AstraZeneca, Pfizer, Amgen all need next-gen obesity assets. Roche acquired Carmot Therapeutics for $2.7B. AZ acquired Eccogene for obesity pipeline.",
    "total_addressable_market_usd_bn": 100
  },
  "query_summary": {
    "as_of": "2026-06-07",
    "condition": "Obesity",
    "deal_type": "both",
    "stage": "both"
  },
  "recent_deal_comps": [
    {
      "deal": "Roche / Carmot Therapeutics",
      "mechanism": "GLP-1 peptide",
      "stage": "PHASE1/2",
      "value_usd_bn": 2.7,
      "year": 2023
    },
    {
      "deal": "AstraZeneca / Eccogene",
      "mechanism": "Small-molecule GLP-1",
      "stage": "PHASE2",
      "value_usd_bn": 1.85,
      "year": 2024
    },
    {
      "deal": "Amgen / ChemoCentryx",
      "mechanism": "C5aR1",
      "stage": "Approved",
      "value_usd_bn": 3.7,
      "year": 2022
    }
  ]
}

# bash or zsh: see the payment challenge. Nothing is charged.
curl -sS -g -i 'https://clinicalintelpulse.theaslangroupllc.com/api/clinical/deal-signal?condition=Disease+area+%E2%80%94+e.g.+%22Obesity%22+%7C+%22Cardiovascular%22+%7C+%22Oncology%22+%7C+%22Rare+Neurological%22+%7C+%22Autoimmune%22&deal_type=acquisition+%7C+licensing+%7C+both+%28default%3A+both%29&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29&stage=phase2+%7C+phase3+%7C+both+%28default%3A+both%29'

# x402 v2 sends the challenge base64-encoded in the PAYMENT-REQUIRED header (v1 sends it in the body).
# To read the header:
curl -sS -g -o /dev/null -D - 'https://clinicalintelpulse.theaslangroupllc.com/api/clinical/deal-signal?condition=Disease+area+%E2%80%94+e.g.+%22Obesity%22+%7C+%22Cardiovascular%22+%7C+%22Oncology%22+%7C+%22Rare+Neurological%22+%7C+%22Autoimmune%22&deal_type=acquisition+%7C+licensing+%7C+both+%28default%3A+both%29&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29&stage=phase2+%7C+phase3+%7C+both+%28default%3A+both%29' \
  | grep -i '^payment-required:' | cut -d' ' -f2 | tr -d '\r' | base64 --decode

// npm i @x402/fetch @x402/evm viem
import { wrapFetchWithPayment, x402Client } from "@x402/fetch";
import { registerExactEvmScheme } from "@x402/evm/exact/client";
import { privateKeyToAccount } from "viem/accounts";

// Pays at most $0.35 per call.
const client = new x402Client().setSpendControls({ maxAmountPerPayment: "$0.35" });
registerExactEvmScheme(client, { signer: privateKeyToAccount(process.env.EVM_PRIVATE_KEY) });
const pay = wrapFetchWithPayment(fetch, client);

// Not sure it's safe to pay? ToolVet checks it first for $0.005. Pay for that from a separate
// client: this one is capped at $0.35 per payment. GET https://toolvet.app/api/v1/check?url=https%3A%2F%2Fclinicalintelpulse.theaslangroupllc.com%2Fapi%2Fclinical%2Fdeal-signal
const res = await pay("https://clinicalintelpulse.theaslangroupllc.com/api/clinical/deal-signal?condition=Disease+area+%E2%80%94+e.g.+%22Obesity%22+%7C+%22Cardiovascular%22+%7C+%22Oncology%22+%7C+%22Rare+Neurological%22+%7C+%22Autoimmune%22&deal_type=acquisition+%7C+licensing+%7C+both+%28default%3A+both%29&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29&stage=phase2+%7C+phase3+%7C+both+%28default%3A+both%29");
console.log(res.status, await res.text());

# pip install "x402[requests,evm]"
import os
from eth_account import Account
from x402 import x402ClientSync
from x402.http.clients import x402_requests
from x402.mechanisms.evm import EthAccountSigner
from x402.mechanisms.evm.exact.register import register_exact_evm_client

# Pays at most $0.35 per call.
client = x402ClientSync().set_spend_controls({"max_amount_per_payment": "$0.35"})
register_exact_evm_client(client, EthAccountSigner(Account.from_key(os.environ["EVM_PRIVATE_KEY"])))

with x402_requests(client) as session:
    res = session.get("https://clinicalintelpulse.theaslangroupllc.com/api/clinical/deal-signal?condition=Disease+area+%E2%80%94+e.g.+%22Obesity%22+%7C+%22Cardiovascular%22+%7C+%22Oncology%22+%7C+%22Rare+Neurological%22+%7C+%22Autoimmune%22&deal_type=acquisition+%7C+licensing+%7C+both+%28default%3A+both%29&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29&stage=phase2+%7C+phase3+%7C+both+%28default%3A+both%29")
    print(res.status_code, res.text)